Literature DB >> 27011339

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Elena H Martinez-Lapiscina1, Sam Arnow2, James A Wilson3, Shiv Saidha4, Jana Lizrova Preiningerova5, Timm Oberwahrenbrock6, Alexander U Brandt6, Luis E Pablo7, Simone Guerrieri8, Ines Gonzalez9, Olivier Outteryck10, Ann-Kristin Mueller11, Phillip Albrecht11, Wesley Chan12, Sebastian Lukas13, Lisanne J Balk14, Clare Fraser15, Jette L Frederiksen16, Jennifer Resto17, Teresa Frohman18, Christian Cordano2, Irati Zubizarreta1, Magi Andorra1, Bernardo Sanchez-Dalmau1, Albert Saiz1, Robert Bermel17, Alexander Klistorner15, Axel Petzold19, Sven Schippling13, Fiona Costello12, Orhan Aktas11, Patrick Vermersch10, Celia Oreja-Guevara9, Giancarlo Comi8, Letizia Leocani8, Elena Garcia-Martin7, Friedemann Paul6, Eva Havrdova5, Elliot Frohman18, Laura J Balcer20, Ari J Green2, Peter A Calabresi4, Pablo Villoslada21.   

Abstract

BACKGROUND: Most patients with multiple sclerosis without previous optic neuritis have thinner retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre layer (pRNFL) thickness and macular volume in eyes with no history of optic neuritis as a biomarker of disability worsening in a cohort of patients with multiple sclerosis who had at least one eye without optic neuritis available.
METHODS: In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association of pRNFL thickness or macular volume at baseline in eyes without optic neuritis with the risk of subsequent disability worsening by use of proportional hazards models that included OCT metrics and age, disease duration, disability, presence of previous unilateral optic neuritis, and use of disease-modifying therapies as covariates.
FINDINGS: 879 patients with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive multiple sclerosis (n=141) were included in the primary analyses. Disability worsening occurred in 252 (29%) of 879 patients with multiple sclerosis after a median follow-up of 2·0 years (range 0·5-5 years). Patients with a pRNFL of less than or equal to 87 μm or less than or equal to 88 μm (measured with Spectralis or Cirrus OCT devices) had double the risk of disability worsening at any time after the first and up to the third years of follow-up (hazard ratio 2·06, 95% CI 1·36-3·11; p=0·001), and the risk was increased by nearly four times after the third and up to the fifth years of follow-up (3·81, 1·63-8·91; p=0·002). We did not identify meaningful associations for macular volume.
INTERPRETATION: Our results provide evidence of the usefulness of monitoring pRNFL thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis. FUNDING: Instituto de Salud Carlos III.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27011339     DOI: 10.1016/S1474-4422(16)00068-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  84 in total

1.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

2.  Active contour method for ILM segmentation in ONH volume scans in retinal OCT.

Authors:  Kay Gawlik; Frank Hausser; Friedemann Paul; Alexander U Brandt; Ella Maria Kadas
Journal:  Biomed Opt Express       Date:  2018-11-28       Impact factor: 3.732

Review 3.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

4.  Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.

Authors:  Janine Mikolajczak; Hanna Zimmermann; Ahmad Kheirkhah; Ella Maria Kadas; Timm Oberwahrenbrock; Rodrigo Muller; Aiai Ren; Joseph Kuchling; Holger Dietze; Harald Prüss; Friedemann Paul; Pedram Hamrah; Alexander U Brandt
Journal:  Mult Scler       Date:  2016-11-03       Impact factor: 6.312

5.  Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

Authors:  Magí Andorrà; Salut Alba-Arbalat; Anna Camos-Carreras; Iñigo Gabilondo; Elena Fraga-Pumar; Ruben Torres-Torres; Irene Pulido-Valdeolivas; Ana I Tercero-Uribe; Ana M Guerrero-Zamora; Santiago Ortiz-Perez; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; Maria Sepulveda; Eugenia Martinez-Hernandez; Thais Armangue; Yolanda Blanco; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz; Elena H Martinez-Lapiscina
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

6.  Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.

Authors:  Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon
Journal:  Neurology       Date:  2019-04-10       Impact factor: 9.910

Review 7.  Optical coherence tomography in multiple sclerosis.

Authors:  Josefine Britze; Jette Lautrup Frederiksen
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

Review 8.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

9.  Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Authors:  Caspar B Seitz; Amgad Droby; Lena Zaubitzer; Julia Krämer; Mathieu Paradis; Luisa Klotz; Heinz Wiendl; Sergiu Groppa; Sven G Meuth; Frauke Zipp; Vinzenz Fleischer
Journal:  J Neurol       Date:  2018-08-02       Impact factor: 4.849

10.  Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.

Authors:  Kimberly M Winges; Charles F Murchison; Dennis N Bourdette; Rebecca I Spain
Journal:  Mult Scler       Date:  2017-11-07       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.